• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Proteostasis Therapeutics

edit

Proteostasis Therapeutics is discovering and developing novel small molecule therapeutics designed to control the body’s protein homeostasis, or Proteostasis Network. The Proteostasis Network maintains the body’s natural balance of proteins to protect us from numerous diseases. These novel therapies, or Proteostasis Regulators, are designed to treat multiple genetic and degenerative disorders associated with deficiencies of the Proteostasis Network, such as emphysema, type II diabetes, Alzheimer’s Disease and Huntington’s Disease.

Recent Milestones

edit

• 
  Proteostasis Therapeutics — stands to make up to $50 million from a collaboration with Dublin biotech Elan Corp (5/25/11)
  Posted 5/25/11 at 7:38am via masshightech.com
• 
  Proteostasis Therapeutics — Elan Corporation PLC (ELN) Makes Investment in Proteostasis Therapeutics, Inc. as Part of $50 Million Neurodegenerative Drug Discovery Partnership (5/25/11)
  Posted 5/25/11 at 6:57pm via biospace.com
• 
  Proteostasis Therapeutics received $45M in Series A funding. (8/25/08)
  Posted 6/21/09 at 11:40pm via reuters.com
• 
  Proteostasis Therapeutics added Mark J. Enyedy as CEO.
  Posted 10/20/11 at 6:39pm
• 
  Proteostasis Therapeutics added Peter H. Reinhart as President and Chief Scientific Officer.
  Posted 10/20/11 at 6:39pm

Videos

Screenshots

edit

Above: Proteostasis Therapeutics
Uploaded: 6/22/09

Sources

1. Proteostasis Therapeutics Secures a $45 Million Series A Financing to Develop Proteostasis Regulator(TM) Drugs (reuters.com) [edit]
Proteostasis forms lucrative drug discovery deal with Elan (masshightech.com) [edit]
Elan Corporation PLC (ELN) Makes Investment in Proteostasis Therapeutics, Inc. as Part of $50 Million Neurodegenerative Drug Discovery Partnership (biospace.com) [edit]